Abstract
Biochemical and Pharmacological Effects of Mitoxantrone and Acetyl-LCarnitine in Mice with a Solid Form of Ehrlich Tumour
Highlights
Since the beginning of 1990, our Laboratories begun a series of in vivo experimental studies to evaluate the effect of carnitine derivatives on the antineoplastic activity of mitoxantrone (MX) a dihydroxyanthracene derivative on various animal models of cancer The objective was to determine pre-clinically whether carnitine and its acyl-derivatives in combination with mitoxantrone could be found to be good candidates to ameliorate host’s metabolic response to tumour processes, and could play a valuable role in the field of cancer treatment
Mitoxantrone (MX), an anthracenedione with a broad spectrum of antitumor activity, is used in the treatment of breast and prostate cancer, acute leukemia, and lymphomas, and since 2000 it has been approved by the U.S Food and Drug Administration (FDA) as an immunomodulatory agent for reducing the neurological disability of worsening relapsing-remitting multiple sclerosis [14]
We previously reported [16] that acetyl carnitine has a mitigating effect on mitoxantrone (MX) toxicity and that it helped to prolong the survival of mice with the ascetic form of leukemia L1210
Summary
Since the beginning of 1990, our Laboratories begun a series of in vivo experimental studies to evaluate the effect of carnitine derivatives on the antineoplastic activity of mitoxantrone (MX) a dihydroxyanthracene derivative on various animal models of cancer The objective was to determine pre-clinically whether carnitine and its acyl-derivatives in combination with mitoxantrone could be found to be good candidates to ameliorate host’s metabolic response to tumour processes, and could play a valuable role in the field of cancer treatment. In this study commented here, we investigated the effect of acetyl-L-Carnitine (ALC) alone and in combination with the antineoplastic agent mitoxantrone (MX) in animal bearing the solid form of Ehrlich tumour (STE).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
